facebook button CodeBreak 200: AMG 510 for Patients with a KRAS p.G12C Mutation
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

CodeBreak 200: AMG 510 for Patients with a KRAS p.G12C Mutation

Sponsor: Amgen Inc.

Protocol 20190009. A phase 3 multicenter, randomized, open label, active-controlled, atudy of AMG 510 versus docetaxel for the treatment of previously treated locally advanced and unresectable or metastatic NSCLC subjects with mutated KRAS p.G12C.

For more information please contact the clinical research department: 631-675-5075